Form 8-K - Current report:
SEC Accession No. 0001193125-24-280155
Filing Date
2024-12-17
Accepted
2024-12-17 09:32:59
Documents
15
Period of Report
2024-12-16
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d875332d8k.htm   iXBRL 8-K 25832
2 EX-99.1 d875332dex991.htm EX-99.1 8318
6 GRAPHIC g875332g0731020058828.jpg GRAPHIC 3024
  Complete submission text file 0001193125-24-280155.txt   161559

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vcnx-20241216.xsd EX-101.SCH 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vcnx-20241216_lab.xml EX-101.LAB 17237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vcnx-20241216_pre.xml EX-101.PRE 10808
18 EXTRACTED XBRL INSTANCE DOCUMENT d875332d8k_htm.xml XML 3533
Mailing Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620
Business Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620 585-271-2700
VACCINEX, INC. (Filer) CIK: 0001205922 (see all company filings)

EIN.: 161603202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38624 | Film No.: 241553839
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)